Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD1 | P21728 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723832 | 0.80 | DRD2 (0.74) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL30737423 | 0.80 | DRD2 (0.57) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL1235246 | 0.80 | MEN1 (0.73) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL11023188 | 0.80 | DRD2 (0.57) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL909770 | 0.79 | DRD2 (0.55) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL28368586 | 0.76 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL11232474 | 0.76 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL31674607 | 0.76 | DRD2 (0.68) | DRD2DRD1TAAR1CHRM2CHRM1 | |
| SCHEMBL5537172 | 0.76 | TAAR1 (0.57) | TAAR1IDO1 | |
| SCHEMBL96829 | 0.76 | TAAR1 (0.57) | TAAR1CHRM2CHRM1CHRM3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| EP-2210900-A2 | Analogues of GLP-1 | IPSEN PHARMA (FR) | 2010-07-28 | — | — | EP | claimed |
| EP-1711523-A4 | ANALOGUES OF GLP-1 | SOD CONSEILS RECH APPLIC (FR) | 2008-05-21 | — | — | EP | claimed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1711523-A1 | ANALOGUES OF GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2006-10-18 | — | — | EP | claimed |
| WO-2005058955-A1 | ANALOGUES OF GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2005-06-30 | — | — | WO | claimed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1711523-A4 | ANALOGUES OF GLP-1 | SOD CONSEILS RECH APPLIC (FR) | 2008-05-21 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1711523-A1 | ANALOGUES OF GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005058955-A1 | ANALOGUES OF GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885 |
| US-20070042952-A1 | Analogues of glp-1 | GLP1R, IAPP, GIPR | DRD2 4408/4885DRD1 4603/4885TAAR1 3616/4885 |
| US-20150299125-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, IRAK1, BTK | DRD2 3159/4885DRD1 3633/4885TAAR1 1221/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.